DigestRedComo funciona
Red
/
Empresas
Ar
No verificado

Arrowhead Pharmaceuticals, Inc.

Sobre qué escribimos

BiotecnologíaCienciaFarmacéuticaMedicina - VariosSalud

79 Comunicados de prensa

Ver todos los comunicados de prensa
05/05/2026
Industria
Cardiología
Biotecnología
Sanidad
Salud
Farmacéutica
Ciencia
Medicina - Varios
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
Fuente
Arrowhead Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
04/05/2026
Eventos
Cardiología
Salud
Sanidad
Comunicación
Farmacéutica
Ciencia
Biotecnología
Medicina - Varios
Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events
Fuente
Arrowhead Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
01/05/2026
Industria
Salud
Biotecnología
Medicina - Varios
Farmacéutica
Cardiología
Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)
Fuente
Arrowhead Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
24/04/2026
Industria
Ciencia
Medicina - Varios
Cardiología
Sanidad
Salud
Farmacéutica
Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe
Fuente
Arrowhead Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
20/04/2026
Web y redes sociales
Telefonía
Finanzas
Mercado de valores
Salud
Biotecnología
Medicina - Varios
Farmacéutica
Cardiología
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results
Fuente
Arrowhead Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
28/03/2026
Eventos
Industria
Salud
Biotecnología
Medicina - Varios
Farmacéutica
Cardiología
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo
Fuente
Arrowhead Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
24/02/2026
Eventos
Web y redes sociales
Farmacéutica
Ciencia
Salud
Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events
Fuente
Arrowhead Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
05/02/2026
Web y redes sociales
Telefonía
Mercado de valores
Ciencia
Farmacéutica
Oncología
VIH, SIDA y enfermedades autoinmunes
Biotecnología
Medicina - Varios
Cardiología
Salud
Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results
Fuente
Arrowhead Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
27/01/2026
Ciencia
Cardiología
Biotecnología
Farmacéutica
Salud
Medicina - Varios
Industria
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
Fuente
Arrowhead Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
20/01/2026
Salud
Biotecnología
Medicina - Varios
Farmacéutica
Web y redes sociales
Telefonía
Finanzas
Mercado de valores
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results
Fuente
Arrowhead Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0